StarZero All shows Try the podcast clipper →

Nov 25, 2021 · 16m · top-founders

MDIHealth Raised $8m, Moving 6 PIlots To Full Time Customers With $1m+ ACV Potential

Ariel Efragan · 8m spoken Nathan Latka · 5m spoken
0:00 / 0:00

gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions

Nathan Latka interviews Ariel Efragan, Head of Growth at MDI Health, exploring how the healthtech startup leverages AI to eliminate adverse drug events, scale multi-million-dollar enterprise contracts, and navigate healthcare commercialization.

How this conversation actually went

Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Nathan holds 38.4% of the talking time here. How this is scored →

Nathan as informed peer 4.6 Guest teaching 3.0 Guest disagreement 2.4 Nathan pushing back 4.8
05100:0010:001:55–6:19 · Nathan as informed peer 5/10 Optimizing Medication Management and Enterprise Pricing Models Latka drills into contract structures and pipeline calculations to ascertain whether clients are in pilots or paying full fees. Efragan explains the healthcare pricing reality involving shared savings, per-member-per-month models, and mandatory clinical validation.6:19–9:12 · Nathan as informed peer 5/10 Head of Growth Responsibilities and Financial Ambitions Latka pushes back firmly when Efragan leans on generic industry buzzwords about health tech being hot, asking for concrete revenue goals like $10M ARR. Efragan resists sharing specific revenue figures while acknowledging the ambition.9:14–11:23 · Nathan as informed peer 4/10 Series A Outlook and Overcoming Recruitment Challenges Latka challenges why recruiting is difficult given the funding and high ACV opportunities. Efragan explains the high burnout and intensity required in mission-driven early-stage startups.11:24–14:00 · Nathan as informed peer 5/10 Ariel's Entrepreneurial History and Patient Care Use Case Latka presses Efragan on the fate of his previous startup, questioning if it was effectively an acquihire due to COVID headwinds. Efragan defends his track record and walks Latka through a tangible hospital patient care use case.14:01–14:31 · Nathan as informed peer 4/10 Churn Assessment and Early Commercial Timeline When Efragan boasts zero churn, Latka immediately challenges the metric by asserting the company is simply too early in its lifecycle to claim meaningful retention. Efragan defends the early retention record.1:55–6:19 · Guest teaching 4/10 Optimizing Medication Management and Enterprise Pricing Models Latka drills into contract structures and pipeline calculations to ascertain whether clients are in pilots or paying full fees. Efragan explains the healthcare pricing reality involving shared savings, per-member-per-month models, and mandatory clinical validation.6:19–9:12 · Guest teaching 2/10 Head of Growth Responsibilities and Financial Ambitions Latka pushes back firmly when Efragan leans on generic industry buzzwords about health tech being hot, asking for concrete revenue goals like $10M ARR. Efragan resists sharing specific revenue figures while acknowledging the ambition.9:14–11:23 · Guest teaching 3/10 Series A Outlook and Overcoming Recruitment Challenges Latka challenges why recruiting is difficult given the funding and high ACV opportunities. Efragan explains the high burnout and intensity required in mission-driven early-stage startups.11:24–14:00 · Guest teaching 4/10 Ariel's Entrepreneurial History and Patient Care Use Case Latka presses Efragan on the fate of his previous startup, questioning if it was effectively an acquihire due to COVID headwinds. Efragan defends his track record and walks Latka through a tangible hospital patient care use case.14:01–14:31 · Guest teaching 2/10 Churn Assessment and Early Commercial Timeline When Efragan boasts zero churn, Latka immediately challenges the metric by asserting the company is simply too early in its lifecycle to claim meaningful retention. Efragan defends the early retention record.1:55–6:19 · Guest disagreement 2/10 Optimizing Medication Management and Enterprise Pricing Models Latka drills into contract structures and pipeline calculations to ascertain whether clients are in pilots or paying full fees. Efragan explains the healthcare pricing reality involving shared savings, per-member-per-month models, and mandatory clinical validation.6:19–9:12 · Guest disagreement 3/10 Head of Growth Responsibilities and Financial Ambitions Latka pushes back firmly when Efragan leans on generic industry buzzwords about health tech being hot, asking for concrete revenue goals like $10M ARR. Efragan resists sharing specific revenue figures while acknowledging the ambition.9:14–11:23 · Guest disagreement 2/10 Series A Outlook and Overcoming Recruitment Challenges Latka challenges why recruiting is difficult given the funding and high ACV opportunities. Efragan explains the high burnout and intensity required in mission-driven early-stage startups.11:24–14:00 · Guest disagreement 3/10 Ariel's Entrepreneurial History and Patient Care Use Case Latka presses Efragan on the fate of his previous startup, questioning if it was effectively an acquihire due to COVID headwinds. Efragan defends his track record and walks Latka through a tangible hospital patient care use case.14:01–14:31 · Guest disagreement 2/10 Churn Assessment and Early Commercial Timeline When Efragan boasts zero churn, Latka immediately challenges the metric by asserting the company is simply too early in its lifecycle to claim meaningful retention. Efragan defends the early retention record.1:55–6:19 · Nathan pushing back 4/10 Optimizing Medication Management and Enterprise Pricing Models Latka drills into contract structures and pipeline calculations to ascertain whether clients are in pilots or paying full fees. Efragan explains the healthcare pricing reality involving shared savings, per-member-per-month models, and mandatory clinical validation.6:19–9:12 · Nathan pushing back 6/10 Head of Growth Responsibilities and Financial Ambitions Latka pushes back firmly when Efragan leans on generic industry buzzwords about health tech being hot, asking for concrete revenue goals like $10M ARR. Efragan resists sharing specific revenue figures while acknowledging the ambition.9:14–11:23 · Nathan pushing back 4/10 Series A Outlook and Overcoming Recruitment Challenges Latka challenges why recruiting is difficult given the funding and high ACV opportunities. Efragan explains the high burnout and intensity required in mission-driven early-stage startups.11:24–14:00 · Nathan pushing back 5/10 Ariel's Entrepreneurial History and Patient Care Use Case Latka presses Efragan on the fate of his previous startup, questioning if it was effectively an acquihire due to COVID headwinds. Efragan defends his track record and walks Latka through a tangible hospital patient care use case.14:01–14:31 · Nathan pushing back 5/10 Churn Assessment and Early Commercial Timeline When Efragan boasts zero churn, Latka immediately challenges the metric by asserting the company is simply too early in its lifecycle to claim meaningful retention. Efragan defends the early retention record.

speaking balance: gold is Nathan, purple is the guest (3 minute bins)

0:00 · Nathan 56.6% · guest 43.4%0:00 · Nathan 56.6% · guest 43.4%3:00 · Nathan 26% · guest 74%3:00 · Nathan 26% · guest 74%6:00 · Nathan 42.4% · guest 57.6%6:00 · Nathan 42.4% · guest 57.6%9:00 · Nathan 31.2% · guest 68.8%9:00 · Nathan 31.2% · guest 68.8%12:00 · Nathan 26.9% · guest 73.1%12:00 · Nathan 26.9% · guest 73.1%15:00 · Nathan 63.3% · guest 36.7%15:00 · Nathan 63.3% · guest 36.7%
Sharpest disagreement ▶ 8:11 Refusal to disclose private financials

Efragan stands firm against Latka's repeated attempts to pin down revenue targets, reiterating that financial metrics will not be shared publicly.

 Hardest push from Nathan ▶ 7:56 Rejecting buzzword justifications

Latka interrupts and refuses Efragan's broad 'hot space' framing, arguing that buzzwords are meaningless without concrete financial scale after an $8M seed round.

 Biggest teaching moment ▶ 4:29 Healthcare stakes in enterprise validation

Efragan educates Latka on why enterprise healthcare pilots cannot convert immediately like food delivery apps, emphasizing the life-or-death stakes of drug interaction algorithms.

 Nathan holds their own ▶ 14:05 Calling out premature zero churn metrics

Latka immediately deflates Efragan's claim of zero churn by highlighting that their commercial history is far too short to treat retention as proven.
the scores for every segment, with the reasoning behind each
ChapterTopicNathan as informed peerGuest teachingGuest disagreementNathan pushing backWhy
Optimizing Medication Management and Enterprise Pricing Models 5424 Latka drills into contract structures and pipeline calculations to ascertain whether clients are in pilots or paying full fees. Efragan explains the healthcare pricing reality involving shared savings, per-member-per-month models, and mandatory clinical validation.
Head of Growth Responsibilities and Financial Ambitions 5236 Latka pushes back firmly when Efragan leans on generic industry buzzwords about health tech being hot, asking for concrete revenue goals like $10M ARR. Efragan resists sharing specific revenue figures while acknowledging the ambition.
Series A Outlook and Overcoming Recruitment Challenges 4324 Latka challenges why recruiting is difficult given the funding and high ACV opportunities. Efragan explains the high burnout and intensity required in mission-driven early-stage startups.
Ariel's Entrepreneurial History and Patient Care Use Case 5435 Latka presses Efragan on the fate of his previous startup, questioning if it was effectively an acquihire due to COVID headwinds. Efragan defends his track record and walks Latka through a tangible hospital patient care use case.
Churn Assessment and Early Commercial Timeline 4225 When Efragan boasts zero churn, Latka immediately challenges the metric by asserting the company is simply too early in its lifecycle to claim meaningful retention. Efragan defends the early retention record.

Statements from this episode (5)

Assertion Partly supported
Medication problems are the fourth leading cause of US deaths
“Problems for medications is the fourth leading cause of death in the U S”
Ariel Efragan Nov 25, 2021 ▶ 1:59
Assertion Not checkable as stated
Enterprise healthcare sales cycles average 12 to 18 months
“So the average sales cycle for enterprise for what we do in healthcare is about 18 months, so 12 to 18 months.”
Ariel Efragan Nov 25, 2021 ▶ 2:15
Assertion Not checkable as stated
Medication management enterprise contracts typically reach millions of dollars
“So contracts in our space are typically in the millions of dollars. We could be, it depends on the size, you know, half a million dollars, something like that. And pilots obviously are cheaper but it just depends on the size of the client, but typically large …”
Ariel Efragan Nov 25, 2021 ▶ 3:03
Assertion Contradicted
MDI Health raised an $8M to $10M seed round
“So we're so we raised about eight million dollars or eight to ten million dollars seed round.”
Ariel Efragan Nov 25, 2021 ▶ 3:31
Prediction Didn’t hold up
MDI Health plans to raise a Series A within 12 months
“We'll probably raise a series a sometime in the next 12 months.”
Ariel Efragan Nov 25, 2021 ▶ 9:32
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 2,600 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more